BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21135089)

  • 1. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.
    Abbasi N; Vadnais B; Knutson JA; Blough DK; Kelly EJ; O'Donnell PV; Deeg HJ; Pawlikowski MA; Ho RJ; McCune JS
    J Clin Pharmacol; 2011 Oct; 51(10):1429-38. PubMed ID: 21135089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation.
    Kim SD; Lee JH; Hur EH; Lee JH; Kim DY; Lim SN; Choi Y; Lim HS; Bae KS; Noh GJ; Yun SC; Han SB; Lee KH
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1222-30. PubMed ID: 21215809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation.
    Sun Y; Huang J; Hao C; Li Z; Liang W; Zhang W; Chen B; Yang W; Hu J
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):293-308. PubMed ID: 31834435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of GST polymorphisms on busulfan pharmacokinetics in Japanese children.
    Nishikawa T; Yamaguchi H; Ikawa K; Nakayama K; Higashi E; Miyahara E; Abematsu T; Nakagawa S; Kodama Y; Tanabe T; Shigemi A; Shinkoda Y; Okamoto Y; Takeda Y; Kawano Y
    Pediatr Int; 2019 Jun; 61(6):558-565. PubMed ID: 30963629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
    Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
    Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Choi B; Kim MG; Han N; Kim T; Ji E; Park S; Kim IW; Oh JM
    Pharmacogenomics; 2015; 16(14):1585-94. PubMed ID: 26419450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation.
    Johnson L; Orchard PJ; Baker KS; Brundage R; Cao Q; Wang X; Langer E; Farag-El Maasah S; Ross JA; Remmel R; Jacobson PA
    J Clin Pharmacol; 2008 Sep; 48(9):1052-62. PubMed ID: 18635758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of glutathione S-transferase A1, P1, M1, T1 polymorphisms on oral busulfan pharmacokinetics in children with congenital hemoglobinopathies undergoing hematopoietic stem cell transplantation.
    Elhasid R; Krivoy N; Rowe JM; Sprecher E; Adler L; Elkin H; Efrati E
    Pediatr Blood Cancer; 2010 Dec; 55(6):1172-9. PubMed ID: 20672371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.
    Kim MG; Kwak A; Choi B; Ji E; Oh JM; Kim K
    Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):691-703. PubMed ID: 30511436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Busulfan in hematopoietic stem cell transplant setting.
    McCune JS; Holmberg LA
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan.
    Kusama M; Kubota T; Matsukura Y; Matsuno K; Ogawa S; Kanda Y; Iga T
    Clin Chim Acta; 2006 Jun; 368(1-2):93-8. PubMed ID: 16448639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.
    Terakura S; Onizuka M; Fukumoto M; Kuwatsuka Y; Kohno A; Ozawa Y; Miyamura K; Inagaki Y; Sawa M; Atsuta Y; Suzuki R; Naoe T; Morishita Y; Murata M;
    Int J Hematol; 2020 Jan; 111(1):84-92. PubMed ID: 31555969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation.
    Bredschneider M; Klein K; Mürdter TE; Marx C; Eichelbaum M; Nüssler AK; Neuhaus P; Zanger UM; Schwab M
    Clin Pharmacol Ther; 2002 Jun; 71(6):479-87. PubMed ID: 12087351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.
    Zwaveling J; Press RR; Bredius RG; van Derstraaten TR; den Hartigh J; Bartelink IH; Boelens JJ; Guchelaar HJ
    Ther Drug Monit; 2008 Aug; 30(4):504-10. PubMed ID: 18641537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation.
    ten Brink MH; van Bavel T; Swen JJ; van der Straaten T; Bredius RG; Lankester AC; Zwaveling J; Guchelaar HJ
    Pharmacogenomics; 2013 Nov; 14(14):1683-90. PubMed ID: 24192117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring.
    Gaziev J; Nguyen L; Puozzo C; Mozzi AF; Casella M; Perrone Donnorso M; Gravina P; Sodani P; Marziali M; Isgrò A; Simone MD; Andreani M; Formosa A; Testi M; Federici G; Bernardini S; Lucarelli G
    Blood; 2010 Jun; 115(22):4597-604. PubMed ID: 20237319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.
    Ansari M; Lauzon-Joset JF; Vachon MF; Duval M; Théoret Y; Champagne MA; Krajinovic M
    Bone Marrow Transplant; 2010 Feb; 45(2):261-7. PubMed ID: 19584821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
    Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
    Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Glutathione S-Transferase Polymorphisms on Busulfan Pharmacokinetics and Outcomes of Hematopoietic Stem Cell Transplantation.
    Al-Riyami I; Al-Khabori M; Al Balushi K; Al-Zadjali S; Al-Rawahi M; Dennison D; Al-Hunaini M; Al-Rawas A; Al-Moundhri M
    Ther Drug Monit; 2022 Aug; 44(4):527-534. PubMed ID: 34990437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.
    Czerwinski M; Gibbs JP; Slattery JT
    Drug Metab Dispos; 1996 Sep; 24(9):1015-9. PubMed ID: 8886613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.